NasdaqGS:ERASBiotechs
Do ERAS-0015 Lawsuits Hint at Deeper Pipeline Concentration Risks for Erasca (ERAS)?
In recent months, multiple law firms have launched class action investigations accusing Erasca of misleading investors about the safety, preclinical data, and intellectual property risks surrounding its lead oncology candidate ERAS-0015, following disclosures of a patient death, adverse clinical findings, and patent infringement claims.
The concentration of legal scrutiny on ERAS-0015 underscores how alleged weaknesses in a single flagship asset’s safety and patent position can reshape...